SCHEMBL4810104

SCHEMBL4810104

C=C(C)C(=O)OCC.C[N+](C)(C)Cl

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.53
TSHR P16473 4/20 0.47
ALDH1A1 P00352 7/20 0.45
LMNA P02545 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GLO1 Q04760 1/20 0.42
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
SOAT1 P35610 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28342228 0.92 ALDH1A1 (0.56) THRBTSHRALDH1A1LMNAHSD17B10
SCHEMBL27832581 0.92 ALDH1A1 (0.56) THRBTSHRALDH1A1LMNAHSD17B10
Methacrylic Acid SCHEMBL27790083 0.92 THRB (0.47) THRBTSHRALDH1A1LMNAHSD17B10
Methylene Chloride SCHEMBL28244287 0.91 THRB (0.57) THRBTSHRALDH1A1LMNAHSD17B10
Chloromethane SCHEMBL17453350 0.89 THRB (0.59) THRBTSHRALDH1A1LMNAHSD17B10
Hydrogen Sulfide SCHEMBL11505632 0.89 THRB (0.59) THRBTSHRALDH1A1LMNAHSD17B10
SCHEMBL19409375 0.89 THRB (0.64) THRBTSHRALDH1A1LMNAHSD17B10
SCHEMBL15030 0.89
SCHEMBL16429830 0.87 THRB (0.53) THRBTSHRALDH1A1LMNAHSD17B10
Acetone SCHEMBL11325819 0.86 THRB (0.61) THRBTSHRALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2124808-A None JP disclosed
US-12636319-B2 Pharmaceutical composition for preventing or treating atopic disease containing Akkermansia muciniphila strain ENTEROBIOME INC. (KR) 2026-05-26 US disclosed
US-12622934-B2 Pharmaceutical composition for preventing or treating atopic disease containing Faecalibacterium prausnitzii strain ENTEROBIOME INC. (KR) 2026-05-12 US disclosed
EP-4698628-A1 AKKERMANSIA BIWAENSIS FOR PREVENTING OR TREATING METABOLIC DISORDERS AND USESE THEREOF ENTEROBIOME INC. (KR) 2026-02-25 EP disclosed
US-20250099511-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER ENTEROBIOME INC. (KR) 2025-03-27 US disclosed
US-20250090534-A1 Phosphodiesterase-5 Inhibitor Combinations, Methods of Making, and Methods of Use Thereof VK RESEARCH ASSOCIATES INC. 2025-03-20 US disclosed
US-20250057893-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR INFLAMMATORY DISEASE ENTEROBIOME INC. (KR) 2025-02-20 US disclosed
EP-4484581-A2 AKKERMANSIA MUCINIPHILA EB-AMDK19 STRAIN AND USE THEREOF ENTEROBIOME INC. (KR) 2025-01-01 EP disclosed
US-20240390429-A1 METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES ENTEROBIOME INC. (KR) 2024-11-28 US disclosed
WO-2024205307-A1 PHARMACEUTICAL COMPOSITION CONTAINING AZILSARTAN FOR TREATING HYPERTENSION ㈜셀트리온 2024-10-03 WO disclosed
US-20220119445-A1 SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF NATIONAL SCIENCE FOUNDATION 2022-04-21 US disclosed
WO-2022076470-A1 ORAL DELAYED BURST FORMULATION OF LOW-DOSE NALTREXONE OR NALOXONE USED FOR|TREATING FIBROMYALGIA AND LONG COVID SORRENTO THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed
EP-3980039-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE CONTAININGAKKERMANSIA MUCINIPHILA ENTEROBIOME INC. (KR) 2022-04-13 EP disclosed
WO-2022045501-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE CONTAINING AKKERMANSIA MUCINIPHILA STRAIN ENTEROBIOME INC. (KR) 2022-03-03 WO disclosed
WO-2022045502-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASE CONTAINING FAECALIBACTERIUM PRAUSNITZII STRAIN ENTEROBIOME INC. (KR) 2022-03-03 WO disclosed
WO-2021080184-A1 SMALL-SIZED, SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING CHOLINE ALFOSCERATE 한국유나이티드제약 주식회사 2021-04-29 WO disclosed
CN-101528237-A Elvucitabine pharmaceutical compositions ACHILLION PHARMACEUTICALS INC (US) 2009-09-09 CN disclosed
US-20080058733-A1 ANTIBIOTIC(S)-POLYMER COMBINATION HERAEUS KULZER GMBH & CO. KG (DE) 2008-03-06 US disclosed
US-20020150549-A1 Antibiotic(s)-polymer combination HERAUES KULZER GMBH & CO.KG (DE) 2002-10-17 US disclosed
JP-H02124808-A DENTURE-BACKING AGENT KOBAYASHI PHARMACEUT CO LTD 1990-05-14 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622934-B2 Pharmaceutical composition for preventing or treating atopic disease containing Faecalibacterium prausnitzii strain TSLP, KLK5, KLK14 THRB 3595/4885TSHR 4359/4885ALDH1A1 3042/4885
US-20220119445-A1 SYNTHETIC CYCLIC PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF VIP, PTMS, IAPP THRB 3085/4885TSHR 2949/4885ALDH1A1 4861/4885
US-12636319-B2 Pharmaceutical composition for preventing or treating atopic disease containing Akkermansia muciniphila strain KLKB1, TSLP, AK1 THRB 1688/4885TSHR 2438/4885ALDH1A1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.